📊 IOVA Key Takeaways
Is Iovance Biotherapeutics, Inc.. (IOVA) a Good Investment?
Iovance is burning substantial cash with operating losses of -$403.4M and free cash flow of -$336.2M despite 60.6% YoY revenue growth, indicating the company is not approaching profitability. The severe negative margins (-153% operating, -148% net) and declining net income quality relative to revenue growth suggest fundamental unit economics problems in the business model. With only $163.1M in cash and current burn rate, runway is critically constrained.
Iovance is delivering strong top-line growth, with revenue up 60.6% year over year, but the business remains deeply unprofitable with operating and net margins worse than -100%. The balance sheet is a clear strength given solid liquidity and no meaningful leverage, yet the scale of operating losses and free cash flow burn suggests growth quality is still weak and execution risk remains high.
Why Buy Iovance Biotherapeutics, Inc.. Stock? IOVA Key Strengths
- Strong revenue growth of 60.6% YoY demonstrates market demand for therapies
- Solid liquidity position with 3.20x current ratio and $163.1M cash reserves
- Reasonable balance sheet structure with 0.00x debt-to-equity and $698.6M stockholders equity
- 16 insider Form 4 filings in last 90 days show ongoing management participation
- Revenue growth is strong at +60.6% YoY, indicating commercial traction
- Balance sheet is relatively healthy with $698.58M of equity and no meaningful debt
- Liquidity is solid with $163.08M in cash, a 3.20x current ratio, and a 2.83x quick ratio
IOVA Stock Risks: Iovance Biotherapeutics, Inc.. Investment Risks
- Extreme cash burn: -$336.2M free cash flow with only $163.1M cash implies <6 months of runway without additional financing
- Deteriorating profitability metrics: operating margin of -153% with net losses expanding, indicating inability to scale efficiently
- High cash burn relative to revenue (127.6% negative FCF margin) suggests core business model may not be viable at current scale
- Growing operating losses of -$403.4M despite strong top-line growth indicates severe unit economics challenges
- Unsustainable burn rate requires continuous dilutive financing to remain solvent
- Operating margin of -153.1% shows the business model is not yet economically sustainable
- Free cash flow of -$336.24M and operating cash flow of -$302.41M imply heavy ongoing cash burn
- Net losses remain very large at $-390.98M, limiting financial flexibility if growth does not translate into better margins
Key Metrics to Watch
- Operating cash flow trend and time to cash flow breakeven
- Cash balance depletion rate relative to monthly burn
- Gross margin improvement as manufacturing scales
- Path to GAAP profitability or evidence of unit-level economics improvement
- Financing activities and dilution from capital raises
- Operating cash flow and free cash flow burn
- Net margin and operating margin improvement
Iovance Biotherapeutics, Inc.. (IOVA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.20x current ratio provides a solid financial cushion.
IOVA Profit Margin, ROE & Profitability Analysis
IOVA vs Healthcare Sector: How Iovance Biotherapeutics, Inc.. Compares
How Iovance Biotherapeutics, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Iovance Biotherapeutics, Inc.. Stock Overvalued? IOVA Valuation Analysis 2026
Based on fundamental analysis, Iovance Biotherapeutics, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Iovance Biotherapeutics, Inc.. Balance Sheet: IOVA Debt, Cash & Liquidity
IOVA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Iovance Biotherapeutics, Inc..'s revenue has grown significantly by 22,062% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.89 indicates the company is currently unprofitable.
IOVA Revenue Growth, EPS Growth & YoY Performance
IOVA Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $58.6M | -$83.5M | N/A |
| Q2 2025 | $31.1M | -$97.1M | $-0.33 |
| Q1 2025 | $715.0K | -$113.0M | $-0.36 |
| Q3 2024 | $469.0K | -$83.5M | $-0.28 |
| Q2 2024 | $238.0K | -$97.1M | $-0.34 |
| Q1 2024 | $715.0K | -$107.4M | $-0.42 |
| Q3 2023 | $469.0K | -$99.6M | $-0.46 |
| Q2 2023 | $238.0K | -$99.3M | $-0.47 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Iovance Biotherapeutics, Inc.. Dividends, Buybacks & Capital Allocation
IOVA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Iovance Biotherapeutics, Inc.. (CIK: 0001425205)
📋 Recent SEC Filings
❓ Frequently Asked Questions about IOVA
What is the AI rating for IOVA?
Iovance Biotherapeutics, Inc.. (IOVA) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 85% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are IOVA's key strengths?
Claude: Strong revenue growth of 60.6% YoY demonstrates market demand for therapies. Solid liquidity position with 3.20x current ratio and $163.1M cash reserves. ChatGPT: Revenue growth is strong at +60.6% YoY, indicating commercial traction. Balance sheet is relatively healthy with $698.58M of equity and no meaningful debt.
What are the risks of investing in IOVA?
Claude: Extreme cash burn: -$336.2M free cash flow with only $163.1M cash implies <6 months of runway without additional financing. Deteriorating profitability metrics: operating margin of -153% with net losses expanding, indicating inability to scale efficiently. ChatGPT: Operating margin of -153.1% shows the business model is not yet economically sustainable. Free cash flow of -$336.24M and operating cash flow of -$302.41M imply heavy ongoing cash burn.
What is IOVA's revenue and growth?
Iovance Biotherapeutics, Inc.. reported revenue of $263.5M.
Does IOVA pay dividends?
Iovance Biotherapeutics, Inc.. does not currently pay dividends.
Where can I find IOVA SEC filings?
Official SEC filings for Iovance Biotherapeutics, Inc.. (CIK: 0001425205) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is IOVA's EPS?
Iovance Biotherapeutics, Inc.. has a diluted EPS of $-1.09.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is IOVA a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Iovance Biotherapeutics, Inc.. has a SELL rating with 85% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is IOVA stock overvalued or undervalued?
Valuation metrics for IOVA: ROE of -56.0% (sector avg: 15%), net margin of -148.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy IOVA stock in 2026?
Our dual AI analysis gives Iovance Biotherapeutics, Inc.. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is IOVA's free cash flow?
Iovance Biotherapeutics, Inc..'s operating cash flow is $-302.4M, with capital expenditures of $33.8M. FCF margin is -127.6%.
How does IOVA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -148.4% (avg: 12%), ROE -56.0% (avg: 15%), current ratio 3.20 (avg: 2).